SIRION Biotech Customised Viral Vectors for Cell Modelling, Gene Therapy, and Vaccination Research and Development

Viral vector systems to improve transduction

SIRION Biotech offers customisation of viral vector systems to improve transduction and performance of in-vitro cell modelling, in-vivo gene modification and therapeutic research and development (R&D). Its applications include custom virus design, virus productions and subsequent cell modelling.

The company’s virus-based technologies are used worldwide in academia and industry. SIRION’s strong focus on transduction technologies enables it to offer custom optimisation of all three major virus types, lentivirus, adenovirus, and adeno-associated virus (AAV).

Viral vector customisation

SIRION engineers and produces lentivirus, AAV, and adenovirus vectors using its in-house technologies. The company offers many add-on options such as inducible expression systems, short hairpin ribonucleic acid (shRNA) driven knockdown, tissue specific promoters and specialised transduction boosters for tight expression control.

All projects are thoroughly discussed with highly trained project managers to ensure resulting vector designs fit the client’s intended application.

Cell modelling by culturing and transducing

SIRION Biotech offers additional services for cell modelling using engineered virus particles to treat custom cell lines. Options include multi-cistronic, inducible gene expression and a combination of knockdown shRNA and overexpression systems.

The company is experienced in culturing and transducing hundreds of standard cell types. Options to develop new standard operating procedures (SOP) for exotic cell types are also possible.

SIRION’s in-house developed transduction boosters enable working with difficult-to-transduce cell types such as hematopoietic cells.

Developing Virus-based Technology

SIRION Biotech is able to address the development of new virus based technologies in cooperation with its industrial partners.

Possible applications include:

  • R&D of new cell-based assays for high-throughput screens (HTS) of compounds in food and cosmetics
  • AAV serotype development by guided evolution to optimise tissue specificities and address production restrictions or safety issues
  • Lentivirus modification to address applicability in chimeric antigen receptor (CAR) T-cell therapies

Liscensing transduction technology

SIRION Biotech offers licensing options for its existing in-house technologies.These include:

  • LentiBOOST: A reagent to increase T-cell transduction with lentivirus. The first clinical applications are pending
  • Ad19a: An adenoviral serotype applicable for transduction of human myoblasts and dendritic cells. It is currently in a pre-clinical phase as vaccination medium

About SIRION Biotech

SIRION Biotech is a globally active technology provider with a strong customer base in the fields of cancer research, neurosciences, regenerative medicines, gene therapy, CAR T-cell development, and R&D of new vaccination methods.

The company was set up in 2007 at the IZB in Martinsried near Munich, Germany. It was designed to shift the paradigm of viral vector technologies and supplies.

Now, the company has more than 500 ongoing projects. SIRION Biotech understands its customers’ technical challenges and offers specialised individual solutions for projects of all sizes.

SIRION BIOTECH’s Chief technology officer (CTO) and founder Christian Thirion said: “Tomorrow’s pharmacological achievements, gene therapy, new vaccination methods, and engineered cell therapy, will be driven by specialised genetic medicines that haven’t even been developed yet.”

Make an enquiry

Follow this company

Follow the company to be always up to date with this company

Press Release

Sirion Biotech to Attend ESGCT XXV Anniversary Congress

Sirion Biotech has announced it will be attending the ESGCT XXV Anniversary Congress, in collaboration with the German Society for Gene Therapy DG-GT.

White Papers

Master Gene Copy Numbers in Hematopoietic Stem Cells

Transduction enhancers help increase the chances of success for blood-cell targeted gene therapies.


Am Klopferspitz 19

82152 Martinsried


+49 897 009 61999 +1 857 284 1844 (US)

SIRION Biotech Images

Products and Services


Related Projects

Press Release

21 September 2017

Sirion Biotech has announced it will be attending the ESGCT XXV Anniversary Congress, in collaboration with the German Society for Gene Therapy DG-GT.

Read more
27 July 2017

Novartis has announced its CAR-T cell therapy CTL019 has been recommended by the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC).

Read more
4 July 2017

Gene delivery by viral vectors has taken centre stage in the development of gene therapies and immuno-oncologies. It has revolutionised the precision that complex cell models can be realised.

Read more
30 May 2017

Off-the shelf virus vectors are naturally limited to answer only a basic set of questions. This can lead experimenters to compromise their work.

Read more
27 April 2017

Known as transduction, the application of virus particles to deliver gene constructs to a cell is one of the best and most efficient ways to genetically modify mammalian or human tissue.

Read more
15 December 2016

Sirion Biotech has announced that the Ad19a/64 vectors, considered by insiders as a promising vaccination and immune oncolgy tool, can act as a powerful prime reagent in a two-step prime boost vaccination approach.

Read more

Regional Offices


Am Klopferspitz 19

82152 Martinsried


+49 897 009 61999 +1 857 284 1844 (US)

Contact company

I have read and accept the terms and conditions and privacy policy.
We'd like to keep you informed about relevant promotions, products and services, if you would like not to receive these, check this box.
If you would like to hear from carefully selected third party companies, check this box
Follow this company to receive notifications when they update.